SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta‐Analyses of Real‐World Evidence
Real-world evidence suggests SGLT2 inhibitors are associated with lower risk of pneumonia, pneumonia-related mortality and sepsis. Given the high burden of infection in this population, these associations deserve further research.
Authors
- George S. Q. Tan (ORCID: https://orcid.org/0000-0003-2526-729X)
- María José Alfonso Arvez (ORCID: https://orcid.org/0000-0003-1411-110X)
- Zanfina Ademi (ORCID: https://orcid.org/0000-0002-0625-3522)
- Miriam T Y Leung (ORCID: https://orcid.org/0000-0002-4259-7058)
- J. Simon Bell (ORCID: https://orcid.org/0000-0002-6115-2767)
Institutions
- Monash Institute of Medical Research (AU)
Publication Details
- Journal
- Journal of Diabetes Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/jdr/5888495
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59